Molecular Partners AG (CH:MOLN)
:MOLN
Total Valuation
Molecular Partners AG has a market cap or net worth of CHF130.21M. The enterprise value is CHF31.20M.
Market CapCHF130.21M
Enterprise ValueCHF31.20M
Share Statistics
Molecular Partners AG has 40,374,640 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding40,374,640
Owned by Insiders―
Owned by Institutions0.03%
Financial Efficiency
Molecular Partners AG’s return on equity (ROE) is -0.77 and return on invested capital (ROIC) is -60.07%.
Return on Equity (ROE)-0.77
Return on Assets (ROA)-0.60
Return on Invested Capital (ROIC)-60.07%
Return on Capital Employed (ROCE)-0.61
Revenue Per Employee0.00
Profits Per Employee-390.20K
Employee Count158
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Molecular Partners AG is ―. Molecular Partners AG’s PEG ratio is -0.54.
PE Ratio―
PS Ratio0.00
PB Ratio1.57
Price to Fair Value1.57
Price to FCF-2.51
Price to Operating Cash Flow-2.37
PEG Ratio-0.54
Income Statement
In the last 12 months, Molecular Partners AG had revenue of 0.00 and earned -61.65M in profits. Earnings per share was -1.65.
Revenue0.00
Gross Profit-2.15M
Operating Income-55.44M
Pretax Income-61.65M
Net Income-61.65M
EBITDA-53.26M
Earnings Per Share (EPS)-1.65
Cash Flow
In the last 12 months, operating cash flow was -50.88M and capital expenditures -714.00K, giving a free cash flow of -51.59M billion.
Operating Cash Flow-50.88M
Free Cash Flow-51.59M
Free Cash Flow per Share-1.28
Dividends & Yields
Molecular Partners AG pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.35
52-Week Price Change1.74%
50-Day Moving Average3.52
200-Day Moving Average3.18
Relative Strength Index (RSI)35.62
Average Volume (3m)17.77K
Important Dates
Molecular Partners AG upcoming earnings date is Aug 31, 2026, TBA (Confirmed).
Last Earnings DateMar 12, 2026
Next Earnings DateAug 31, 2026
Ex-Dividend Date―
Financial Position
Molecular Partners AG as a current ratio of 8.79, with Debt / Equity ratio of 4.54%
Current Ratio8.79
Quick Ratio8.79
Debt to Market Cap0.00
Net Debt to EBITDA1.48
Interest Coverage Ratio-15.84
Taxes
In the past 12 months, Molecular Partners AG has paid 2.00K in taxes.
Income Tax2.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Molecular Partners AG EV to EBITDA ratio is -0.89, with an EV/FCF ratio of -0.94.
EV to Sales0.00
EV to EBITDA-0.89
EV to Free Cash Flow-0.94
EV to Operating Cash Flow-0.96
Balance Sheet
Molecular Partners AG has CHF93.10M in cash and marketable securities with CHF3.64M in debt, giving a net cash position of CHF89.46M billion.
Cash & Marketable SecuritiesCHF93.10M
Total DebtCHF3.64M
Net CashCHF89.46M
Net Cash Per ShareCHF2.22
Tangible Book Value Per ShareCHF2.16
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Molecular Partners AG is CHF15.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetCHF15.00
Price Target Upside339.88% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast-100.00%
EPS Growth Forecast14.45%